125 filings
Page 2 of 7
6-K
juk nvhhs
18 Aug 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:07pm
6-K
6awcwese2b3p03mpt7
12 Aug 20
Genmab Announces Financial Results for the First Half of 2020
3:22pm
6-K
t6n5l77inll3 t7x
31 Jul 20
Current report (foreign)
4:49pm
6-K
k2z oih5qedeiza6wxzm
20 Jul 20
Major Shareholder Announcement
1:09pm
6-K
evoxl0nhe0bp8s8ftw
16 Jul 20
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
10:05am
6-K
u2dfibsbuhowokvqo
7 Jul 20
Major Shareholder Announcement
11:19am
6-K
pqfgxazefsd4ds6gry7
6 Jul 20
Major Shareholder Announcement
1:57pm
6-K
1wlx xqlwat
6 Jul 20
Major Shareholder Announcement
1:54pm
6-K
qhg hgnfv
1 Jul 20
Current report (foreign)
10:58am
6-K
38b3 4ex8
30 Jun 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
3:16pm
6-K
3hlg83
29 Jun 20
Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
12:00am
6-K
i20 33eghximd3kd2
11 Jun 20
Current report (foreign)
9:40am
6-K
u0r6563b
10 Jun 20
Genmab and AbbVie Announce Broad Oncology Collaboration
7:33am
6-K
k6c1dh 37
4 Jun 20
Subcutaneous fixed-dosed formulation of DARZALEX® (daratumumab) approved in Europe for the treatment of adult patients with multiple myeloma
10:55am
6-K
6ea8 3dvca1
3 Jun 20
Current report (foreign)
4:48pm
6-K
7yadp i3i5
28 May 20
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
4:14pm
6-K
3rdli
13 May 20
Current report (foreign)
2:47pm
6-K
2i71io tk7
12 May 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2:00pm
6-K
wcx dw8vb
6 May 20
Genmab Announces Financial Results for the First Quarter of 2020
2:31pm
6-K
k3aoj7d4q anw
1 May 20
Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple myeloma
3:02pm